Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110712 | 0.88 | NPY1R (0.78) | NPY1RKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL7042428 | 0.85 | NPY1R (0.74) | NPY1RKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL7038636 | 0.81 | NPY1R (0.74) | NPY1RKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL7045715 | 0.78 | NPY1R (0.64) | NPY1RKDM4EALDH1A1CRHR1 | |
| SCHEMBL7044370 | 0.76 | NPY1R (0.69) | NPY1RKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL1594052 | 0.76 | NPY1R (0.66) | NPY1RKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL7041881 | 0.76 | NPY1R (0.61) | NPY1RKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL7041955 | 0.76 | NPY1R (1.00) | NPY1RKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL7046270 | 0.73 | NPY1R (0.70) | NPY1RKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL5728795 | 0.73 | NPY1R (0.81) | NPY1RKDM4EMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6372743-B1 | EATING DISORDERS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | NEUROGEN CORPORATION | 2002-04-16 | — | — | US | claimed |
| US-6602508-B2 | Reacting with a base to form a de-n-acetylated product, and depolymerizing with a nitrosation agent | BAXTER INTERNATIONAL INC. | 2003-08-05 | — | — | US | disclosed |
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION (US) | 2003-04-10 | — | — | US | disclosed |
| EP-0830380-B1 | ANTIGENIC GROUP B STREPTOCOCCUS TYPE II AND TYPE III POLYSACCHARIDE FRAGMENTS HAVING A 2, 5-ANHYDRO-D-MANNOSE TERMINAL STRUCTURE AND CONJUGATE VACCINE THEREOF | NORTH AMERICAN VACCINE INC (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1218379-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6372743-B1 | EATING DISORDERS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | NEUROGEN CORPORATION | 2002-04-16 | — | — | US | disclosed |
| US-6372222-B1 | Antigenic group B Streptococcus type II and type III polysaccharide fragments having a 2, 5-anhydro-D-mannose terminal structure and conjugate vaccine thereof | BAXTER INTERNATIONAL INC. | 2002-04-16 | — | — | US | disclosed |
| US-20020031526-A1 | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2, 5-anhydro-D-mannose terminal structure and conjugate vaccine thereof | MICHON FRANCIS (US) | 2002-03-14 | — | — | US | disclosed |
| US-6284884-B1 | DEPOLYMERIZATION AND REACTING WITH BASE TO FORM DE-N-ACETYLATED POLYSACCHARIDE; REACTING WITH NITROSATION AGENT | NORTH AMERICAN VACCINE, INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2001023387-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-0830380-A1 | ANTIGENIC GROUP B STREPTOCOCCUS TYPE II AND TYPE III POLYSACCHARIDE FRAGMENTS HAVING A 2, 5-ANHYDRO-D-MANNOSE TERMINAL STRUCTURE AND CONJUGATE VACCINE THEREOF | NORTH AMERICAN VACCINE, INC. (CA) | 1998-03-25 | — | — | EP | disclosed |
| WO-1996040795-A1 | ANTIGENIC GROUP B STREPTOCOCCUS TYPE II AND TYPE III POLYSACCHARIDE FRAGMENTS HAVING A 2, 5-ANHYDRO-D-MANNOSE TERMINAL STRUCTURE AND CONJUGATE VACCINE THEREOF | NORTH AMERICAN VACCINE, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020031526-A1 | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2, 5-anhydro-D-mannose terminal structure and conjugate vaccine thereof | ST3GAL3, MASP2, FUT5 | NPY1R 994/4885KDM4E 2853/4885ALDH1A1 4239/4885 |
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NPY1R, NPY5R, NPY2R | NPY1R 1/4885KDM4E 1742/4885ALDH1A1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.